1 ML satralizumab-mwge 120 MG/ML Prefilled Syringe [Enspryng]
NO BLACK BOX WARNING
Dosage & administration
Most viewed Enspryng resources
Enroll in Patient Savings Program
drug label
Enspryng prescribing information
Have more Enspryng questions?
Submit MSL Request
Learn More
Your request will be referred to the appropriate Genentech Inc. medical professional, such as a Enspryng pharmaceutical rep; Medical Science Liaison (MSL) or medical affairs.
Need to report an Enspryng issue?
ONLINE FORMReport adverse event
Learn More
You can report a Enspryng adverse event on MedWatch, the FDA's medical product safety reporting program for health professionals, patients and consumers.
prior authorization
Enspryng Prior authorization resources
Complete Letter of Medical Necessity
NOT PROVIDED BY BRANDCoverage Authorization Request
Coverage Authorization Appeals
Learn More
If available, these templates are provided by the brand to help you navigate insurance, especially with newer drugs.
Benefits investigation
Enspryng Start Form
Learn More
Benefits investigations are conducted to determine whether a therapy is covered under a patient's insurance, if a prior authorization is required, and which specialty pharmacies are preferred.
Reimbursement help (FRM)
NOT PROVIDED BY BRANDReimbursement help (FRM) resources
Learn More
Some brands offer a field reimbursement manager who will work with your clinical staff and preferred pharmacy to help make sure patients don't fall through the cracks.
financial assistance
Enspryng Financial assistance options
Co-pay savings program
commercial only
Enroll in Patient Savings Program
Enspryng Start Form
Learn More
Overview
Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)
Patient benefit
A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max
Patient eligibility
Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance
How to sign up
Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form
Bridge program
commercial only
Learn More
Overview
Provide patient immediate access to therapy during an insurance delay (typically new starts; some may cover change in insurance)
Limited time/ fill (typically 7-30 days; some may offer additional fill for continued delay up to certain limit)
Patient benefit
100% free (outside of insurance)
Patient eligibility
HCP must enroll patient
May be limited to commercially insured patients (i.e., no government beneficiaries); some programs may allow government beneficiaries
How to sign up
Typically HCP assisted enrollment (via form)
Foundation programs
under insured
no insurance
goverment insurance
65+
Genentech Patient Assistance Program Application - Online, Prescriber Form
Genentech Patient Assistance Program Application - Online, Patient Consent Form
Genentech Patient Assistance Program Application - PDF, Prescriber Form
Genentech Patient Assistance Program Application - PDF, Patient Consent Form
Learn More
Overview
Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned
Patient benefit
Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and co-pays) until the grant is exhausted
Patient eligibility
Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.
How to sign up
Patients submit proof of out-of-pocket drug costs to charities for reimbursement
patient education
Enspryng Patient education
Getting started on Enspryng
Instructions For Use - Neuromyelitis Optica Spectrum Disorder (NMOSD)
ASK PATIENT TO: Open Camera on Phone Scan QR Code & Tap Link
Patient toolkit
About Enspryng
ASK PATIENT TO: Open Camera on Phone Scan QR Code & Tap Link
Patient Stories
ASK PATIENT TO: Open Camera on Phone Scan QR Code & Tap Link
Patient Resources
ASK PATIENT TO: Open Camera on Phone Scan QR Code & Tap Link
Learn More
Other resources brands publish to help support patients and caregivers.
people also ask
Enspryng FAQs
Is there a pregnancy exposure registry for ENSPRYNG?Yes, there is a pregnancy exposure registry for ENSPRYNG that monitors pregnancy outcomes in women exposed to the drug during pregnancy. Healthcare providers are encouraged to register patients, and pregnant women are encouraged to register themselves by calling 1-833-277-9338.
What is the risk of using ENSPRYNG during pregnancy?There are no adequate data on the developmental risk associated with the use of ENSPRYNG in pregnant women. In the U.S. general population, the estimated background risk of major birth defect and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown.
Is satralizumab-mwge present in human milk?No information is available on the presence of satralizumab-mwge in human milk. Satralizumab-mwge was excreted in the milk of lactating monkeys administered satralizumab-mwge throughout pregnancy. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for ENSPRYNG and any potential adverse effects on the breastfed infant from ENSPRYNG or from the underlying maternal condition.
Is ENSPRYNG safe and effective for use in pediatric patients?Safety and effectiveness in pediatric patients have not been established.
Are there any specific considerations for dosing ENSPRYNG in elderly patients?Clinical studies of ENSPRYNG did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently from younger patients. In general, caution should be used when dosing the elderly, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant diseases or other drug therapy.
FAQ Data Source
We receive information directly from the FDA and PrescriberPoint is updated as frequently as change are made available
Can't find what you're looking for?
Our trained staff can help you:
Please note:
Access to a Field Reimbursement Manager (FRM) or Medical Science Liaison (MSL) varies by brand and may require talking with your rep first.
Samples are provided at the discretion of the brand.
We are unable to collect Protected Health Information (PHI), fill out forms, or submit them on your behalf.